Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | CSF1R | P07333 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 4/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893609 | 0.88 | IMPDH2 (0.64) | MAPK14LCKCSF1RKDREGFR | |
| SCHEMBL13198135 | 0.86 | MAPK14 (0.58) | MAPK14LCKCSF1RKDREGFR | |
| SCHEMBL13198118 | 0.85 | MEN1 (0.59) | MAPK14LCKCSF1RKDREGFR | |
| SCHEMBL13198125 | 0.84 | MAPK14 (0.53) | MAPK14LCKCSF1RKDREGFR | |
| SCHEMBL13198122 | 0.83 | MAPK14 (0.53) | MAPK14LCKCSF1RKDREGFR | |
| SCHEMBL13198132 | 0.83 | MAPK14 (0.53) | MAPK14LCKCSF1RKDREGFR | |
| SCHEMBL13198108 | 0.83 | IMPDH2 (0.72) | MAPK14LCKCSF1RKDREGFR | |
| SCHEMBL13198126 | 0.83 | LCK (0.57) | MAPK14LCKCSF1RKDREGFR | |
| SCHEMBL13198115 | 0.82 | IMPDH2 (0.55) | MAPK14LCKCSF1RKDREGFR | |
| SCHEMBL13198113 | 0.81 | POLB (0.56) | MAPK14LCKCSF1RKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MSD K.K. (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197688-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | MAPK14 146/4885LCK 140/4885CSF1R 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.